Xbrane Expands Capacity To Target More Biosimilars
Eyeing Further Blockbuster Biologics After Move To Solna Premises
Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.
You may also be interested in...
Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months
Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.